<?xml version="1.0" encoding="UTF-8"?>
<cas:metadata xmlns:cas="http://oodt.jpl.nasa.gov/1.0/cas">
<keyval type="vector">
<key>ProductTitle</key>
<val>PLCO+Biomarker+Performance+Analysis+%E2%80%93+all+institutions</val>
<val>PLCO+Biomarker+Performance+Analysis+%E2%80%93+all+institutions</val>
</keyval>
<keyval type="vector">
<key>CAS.ProductId</key>
<val>021b5fc4-50e7-11df-973d-17ec13bf30a1</val>
</keyval>
<keyval type="vector">
<key>ProductDescription</key>
<val>Contains+the+data+for+markers+measured+from+all+institutions+validating+markers+with+PLCO+specimens%0A++</val>
<val>Contains+the+data+for+markers+measured+from+all+institutions+validating+markers+with+PLCO+specimens%0A++</val>
</keyval>
<keyval type="vector">
<key>SiteShortName</key>
<val>bgwm</val>
</keyval>
<keyval type="vector">
<key>DateProductFrozen</key>
<val>2-25-2010</val>
<val>2-25-2010</val>
</keyval>
<keyval type="vector">
<key>Filename</key>
<val>ovarian_marker_all_08_27_09_with_SLPI_02252010.xls</val>
</keyval>
<keyval type="vector">
<key>LabAnalyticMethods</key>
<val>N%2FA</val>
<val>N%2FA</val>
</keyval>
<keyval type="vector">
<key>DataStage</key>
<val>Processed</val>
<val>Processed</val>
</keyval>
<keyval type="vector">
<key>CAS.ProductName</key>
<val>ovarian_marker_all_08_27_09_with_SLPI_02252010.xls</val>
</keyval>
<keyval type="vector">
<key>ProductType</key>
<val>BGWHCramerPLCOPhaseIIIAnalysis</val>
</keyval>
<keyval type="vector">
<key>ProductFunction</key>
<val>Claire+Zhu+and+Allison+Vitonis.</val>
<val>Claire+Zhu+and+Allison+Vitonis.</val>
</keyval>
<keyval type="vector">
<key>FileLocation</key>
<val>%2Fdata%2Fingest%2Fplco%2Fslpi</val>
</keyval>
<keyval type="vector">
<key>InstrumentDetails</key>
<val>N%2FA</val>
<val>N%2FA</val>
</keyval>
<keyval type="vector">
<key>MethodDetails</key>
<val>PLCO+datasets+%28Phase+III%29%3A%0A++The+Phase+III+study+was+coordinated+by+the+PLCO.++Sample+collection%2C+processing%2C+shipping+and+storage+were+standardized+%0A++across+all+screening+sites.++Briefly%2C+blood+was+drawn+and+processed+within+2+hours+into+vials+%28%7E1.8ml%29+of+serum%2Fplasma%2C+%0A++buffy+coat+and+red+blood+cells.+A+unique+specimen+identification+number+was+generated+for+each+vial+and+daughter+vial+created.++%0A++Vials+were+stored+at+-70+%C2%B0C+and+shipped+to+the+central+biorepository+overnight+on+dry+ice+for+long-term+storage+at+-70%C2%B0C+or+-157+%C2%B0C.+%0A++%0A++By+June+of+2006%2C+118+cases+of+invasive+ovarian%2C+primary+peritoneal%2C+and+fallopian+tube+cancers+with+available+samples+had+been+confirmed.+%0A++Tumors+of+%E2%80%9Cborderline+malignancy%E2%80%9D+were+excluded.++++Serum+samples+most+proximate+to+diagnosis+were+selected.++Controls+were+selected+from+%0A++a+pool+of+healthy+individuals+who+remained+cancer+free+and+were+matched+to+cases+by+five+year+age+categories+at+blood+draw%2C+calendar+year+%0A++of+blood+draw.++Women+who+reported+a+history+of+cancer+or+oophorectomy+at+baseline+were+excluded+from+control+selection.+For+each+case%2C+%0A++8+healthy+controls+were+selected%3A+4+randomly+selected+from+a+pool+of+all+eligible+controls+and+representing+general+population+controls%3B+%0A++2+with+positive+family+history+of+breast+or+ovarian+cancer%3B+and+2+with+history+of+an+elevated+CA125.++Sixty+replicate+pairs+were+randomly+%0A++inserted+into+the+batches+for+blinded+QC%3B+ten+pairs+of+which+had+CA125+values+greater+than+25+U%2Fml.++%0A++%0A++PLCO+serum+samples+to+be+allocated+are+at+the+PLCO+biorepository+in+Frederick%2C+Md.+One+vial+containing+1.8ml+of+serum+was+pulled+from+the+PLCO+%0A++biorepository+for+each+selected+subject+and+was+sent+to+the+PLCO+central+processing+lab+for+aliquoting.+Aliquots+of+desired+amounts+for+each+%0A++investigator+teams+were+made+side+by+side+in+small+batches+to+avoid+repeated+freeze-thaw%2C+and+to+minimize+variability+in+handling.++FHCRC+%0A++received+0.3+ml%2C+MDACC+0.1+ml%2C+Partners+two+0.6ml+aliquots%2C+and+Pittsburgh+0.2+ml%2C+and+YUSM+0.2+ml.++Aliquots+were+labeled+with+a+unique+sample+%0A++ID%2C+and+were+randomly+ordered+such+that+cases+and+controls+were+evenly+distributed%2C+then+packed+into+81-cell+freezer+boxes+and+kept+frozen.+Prior+%0A++to+shipping%2C+the+laboratories+were+notified+of+the+shipment+24+hours+in+advance.+Aliquots+were+shipped+overnight+on+dry+ice.++A+shipping+manifest+%0A++containing+aliquot+IDs+was+included+in+the+package+and+was+also+emailed+to+the+laboratories.++Each+laboratory+received+aliquots+of+identical+sets+%0A++of+samples.+%0A++%0A++Laboratory+Assays%0A++%0A++Laboratory+assays+for+the+phase+III+PLCO+study+were+conducted+at+the+four+separate+laboratories+by+individuals+who+were+blind+to+case+or+control+%0A++status+for+both+the+phase+II+and+phase+III+specimens.++Assays+included+single-+or+multi-plex+Luminex+bead+assays%2C+plate-based+ELISA+assays%2C+platform-based+%0A++%28Roche+E170%29+assays%2C+and+a+mass+spectroscopy-based+system+using+surface+enhanced+antibody+chips.++With+the+exceptions+noted+below%2C+the+assays+used+for+the+%0A++phase+III+specimens+were+also+used+for+the+phase+II+specimens.%0A++%0A++At+FHCRC+single-plex+Luminex+bead+assays+were+used+for+all+markers%2C+details+of+which+can+be+found+in+%28Shah+CA%2C+Lowe+KA%2C+Paley+P%2C+Wallace+E%2C+Anderson+GL%2C+McIntosh+%0A++MW%2C+Andersen+MR%2C+Scholler+N%2C+Bergan+LA%2C+Thorpe+JD%2C+Urban+N%2C+and+Drescher+CW%2C+Influence+of+ovarian+cancer+risk+status+on+the+diagnostic+performance+of+the+serum+%0A++biomarkers+mesothelin%2C+HE4%2C+and+CA125.+Cancer+Epidemiol+Biomarkers+Prev%2C+2009.+18%285%29%3A+p.+1365-72.%29.+++The+same+assays+were+carried+over+into+phase+III+except+that+%0A++a+plate+based+assay+for+MMP-7+was+introduced.++MDACC+used+a+mass+spectroscopy+based+system+for+its+markers+in+both+phases++further+described+in+%28Zhang+Z%2C+Bast+RC%2C+%0A++Jr.%2C+Yu+Y%2C+Li+J%2C+Sokoll+LJ%2C+Rai+AJ%2C+Rosenzweig+JM%2C+Cameron+B%2C+Wang+YY%2C+Meng+XY%2C+Berchuck+A%2C+Van+Haaften-Day+C%2C+Hacker+NF%2C+de+Bruijn+HW%2C+van+der+Zee+AG%2C+Jacobs+IJ%2C+Fung+%0A++ET%2C+and+Chan+DW%2C+Three+biomarkers+identified+from+serum+proteomic+analysis+for+the+detection+of+early+stage+ovarian+cancer.+Cancer+Res%2C+2004.+64%2816%29%3A+p.+5882-90.%29.+%0A++Partners+used+plate-based+assay+for+B7-H4%28Diadexus%29%2C+DcR3%28Diadexus%29%2C+CA72.4%2C+IGF+2%2C+Mesothelin%2C+HE4%2C+and+Kallikrein+6+%28as+described+in+%28Diamandis+EP%2C+Scorilas+A%2C+Fracchioli+S%2C+%0A++Van+Gramberen+M%2C+De+Bruijn+H%2C+Henrik+A%2C+Soosaipillai+A%2C+Grass+L%2C+Yousef+GM%2C+Stenman+UH%2C+Massobrio+M%2C+Van+Der+Zee+AG%2C+Vergote+I%2C+and+Katsaros+D%2C+Human+kallikrein+6+%28hK6%29%3A+%0A++a+new+potential+serum+biomarker+for+diagnosis+and+prognosis+of+ovarian+carcinoma.+J+Clin+Oncol%2C+2003.+21%286%29%3A+p.+1035-43%29%29.++Platform-based+assays+%28Roche%29+were+used+for+CA125%2C+%0A++CA15.3%2C+CA19.9%2C+and+CEA.++Unless+the+volume+was+insufficient+assays+were+run+in+duplicate+and+averaged.++Seven+markers+were+carried+over+to+phase+III+and+these+included+%0A++B7H4%2C+CA125%2C+CA15.3%2C+CA19.9%2C+CA72.4%2C+HE4%2C+and+HK+6.+++The+same+assays+were+used+except+that+a+platform-based+assay+was+available+for+CA72.4.+++The+two+0.3+aliquots+were+%0A++first+combined+and+homogenized.++UPCI+used+a+multi-plex+bead+assay+system+was+used+to+evaluate+34+markers+in+phase+II.++This+technique+is+described+in+%28Nolen+B%2C+Marrangoni+%0A++A%2C+Velikokhatnaya+L%2C+Prosser+D%2C+Winans+M%2C+Gorelik+E%2C+and+Lokshin+A%2C+A+serum+based+analysis+of+ovarian+epithelial+tumorigenesis.+Gynecol+Oncol%2C+2009.+112%281%29%3A+p.+47-54%29.++For+%0A++phase+III%2C+the+number+of+markers+was+reduced+to+8+but+the+same+technique+was+used.++For+the+phase+II+markers+included+in+the+Yale+panel%2C+these+markers+were+evaluated+using+a+%0A++multi-plex+bead+system+described+in+%28Visintin+I%2C+Feng+Z%2C+Longton+G%2C+Ward+DC%2C+Alvero+AB%2C+Lai+Y%2C+Tenthorey+J%2C+Leiser+A%2C+Flores-Saaib+R%2C+Yu+H%2C+Azori+M%2C+Rutherford+T%2C+Schwartz+PE%2C+%0A++and+Mor+G%2C+Diagnostic+markers+for+early+detection+of+ovarian+cancer.+Clin+Cancer+Res%2C+2008.+14%284%29%3A+p.+1065-72%29.++For+the+phase+III+specimens+the+same+markers+were+carried+over+%0A++but+the+analyses+were+performed+by+Laboratory+Corporation+of+America.%0A++</val>
<val>PLCO+datasets+%28Phase+III%29%3A%0A++The+Phase+III+study+was+coordinated+by+the+PLCO.++Sample+collection%2C+processing%2C+shipping+and+storage+were+standardized+%0A++across+all+screening+sites.++Briefly%2C+blood+was+drawn+and+processed+within+2+hours+into+vials+%28%7E1.8ml%29+of+serum%2Fplasma%2C+%0A++buffy+coat+and+red+blood+cells.+A+unique+specimen+identification+number+was+generated+for+each+vial+and+daughter+vial+created.++%0A++Vials+were+stored+at+-70+%C2%B0C+and+shipped+to+the+central+biorepository+overnight+on+dry+ice+for+long-term+storage+at+-70%C2%B0C+or+-157+%C2%B0C.+%0A++%0A++By+June+of+2006%2C+118+cases+of+invasive+ovarian%2C+primary+peritoneal%2C+and+fallopian+tube+cancers+with+available+samples+had+been+confirmed.+%0A++Tumors+of+%E2%80%9Cborderline+malignancy%E2%80%9D+were+excluded.++++Serum+samples+most+proximate+to+diagnosis+were+selected.++Controls+were+selected+from+%0A++a+pool+of+healthy+individuals+who+remained+cancer+free+and+were+matched+to+cases+by+five+year+age+categories+at+blood+draw%2C+calendar+year+%0A++of+blood+draw.++Women+who+reported+a+history+of+cancer+or+oophorectomy+at+baseline+were+excluded+from+control+selection.+For+each+case%2C+%0A++8+healthy+controls+were+selected%3A+4+randomly+selected+from+a+pool+of+all+eligible+controls+and+representing+general+population+controls%3B+%0A++2+with+positive+family+history+of+breast+or+ovarian+cancer%3B+and+2+with+history+of+an+elevated+CA125.++Sixty+replicate+pairs+were+randomly+%0A++inserted+into+the+batches+for+blinded+QC%3B+ten+pairs+of+which+had+CA125+values+greater+than+25+U%2Fml.++%0A++%0A++PLCO+serum+samples+to+be+allocated+are+at+the+PLCO+biorepository+in+Frederick%2C+Md.+One+vial+containing+1.8ml+of+serum+was+pulled+from+the+PLCO+%0A++biorepository+for+each+selected+subject+and+was+sent+to+the+PLCO+central+processing+lab+for+aliquoting.+Aliquots+of+desired+amounts+for+each+%0A++investigator+teams+were+made+side+by+side+in+small+batches+to+avoid+repeated+freeze-thaw%2C+and+to+minimize+variability+in+handling.++FHCRC+%0A++received+0.3+ml%2C+MDACC+0.1+ml%2C+Partners+two+0.6ml+aliquots%2C+and+Pittsburgh+0.2+ml%2C+and+YUSM+0.2+ml.++Aliquots+were+labeled+with+a+unique+sample+%0A++ID%2C+and+were+randomly+ordered+such+that+cases+and+controls+were+evenly+distributed%2C+then+packed+into+81-cell+freezer+boxes+and+kept+frozen.+Prior+%0A++to+shipping%2C+the+laboratories+were+notified+of+the+shipment+24+hours+in+advance.+Aliquots+were+shipped+overnight+on+dry+ice.++A+shipping+manifest+%0A++containing+aliquot+IDs+was+included+in+the+package+and+was+also+emailed+to+the+laboratories.++Each+laboratory+received+aliquots+of+identical+sets+%0A++of+samples.+%0A++%0A++Laboratory+Assays%0A++%0A++Laboratory+assays+for+the+phase+III+PLCO+study+were+conducted+at+the+four+separate+laboratories+by+individuals+who+were+blind+to+case+or+control+%0A++status+for+both+the+phase+II+and+phase+III+specimens.++Assays+included+single-+or+multi-plex+Luminex+bead+assays%2C+plate-based+ELISA+assays%2C+platform-based+%0A++%28Roche+E170%29+assays%2C+and+a+mass+spectroscopy-based+system+using+surface+enhanced+antibody+chips.++With+the+exceptions+noted+below%2C+the+assays+used+for+the+%0A++phase+III+specimens+were+also+used+for+the+phase+II+specimens.%0A++%0A++At+FHCRC+single-plex+Luminex+bead+assays+were+used+for+all+markers%2C+details+of+which+can+be+found+in+%28Shah+CA%2C+Lowe+KA%2C+Paley+P%2C+Wallace+E%2C+Anderson+GL%2C+McIntosh+%0A++MW%2C+Andersen+MR%2C+Scholler+N%2C+Bergan+LA%2C+Thorpe+JD%2C+Urban+N%2C+and+Drescher+CW%2C+Influence+of+ovarian+cancer+risk+status+on+the+diagnostic+performance+of+the+serum+%0A++biomarkers+mesothelin%2C+HE4%2C+and+CA125.+Cancer+Epidemiol+Biomarkers+Prev%2C+2009.+18%285%29%3A+p.+1365-72.%29.+++The+same+assays+were+carried+over+into+phase+III+except+that+%0A++a+plate+based+assay+for+MMP-7+was+introduced.++MDACC+used+a+mass+spectroscopy+based+system+for+its+markers+in+both+phases++further+described+in+%28Zhang+Z%2C+Bast+RC%2C+%0A++Jr.%2C+Yu+Y%2C+Li+J%2C+Sokoll+LJ%2C+Rai+AJ%2C+Rosenzweig+JM%2C+Cameron+B%2C+Wang+YY%2C+Meng+XY%2C+Berchuck+A%2C+Van+Haaften-Day+C%2C+Hacker+NF%2C+de+Bruijn+HW%2C+van+der+Zee+AG%2C+Jacobs+IJ%2C+Fung+%0A++ET%2C+and+Chan+DW%2C+Three+biomarkers+identified+from+serum+proteomic+analysis+for+the+detection+of+early+stage+ovarian+cancer.+Cancer+Res%2C+2004.+64%2816%29%3A+p.+5882-90.%29.+%0A++Partners+used+plate-based+assay+for+B7-H4%28Diadexus%29%2C+DcR3%28Diadexus%29%2C+CA72.4%2C+IGF+2%2C+Mesothelin%2C+HE4%2C+and+Kallikrein+6+%28as+described+in+%28Diamandis+EP%2C+Scorilas+A%2C+Fracchioli+S%2C+%0A++Van+Gramberen+M%2C+De+Bruijn+H%2C+Henrik+A%2C+Soosaipillai+A%2C+Grass+L%2C+Yousef+GM%2C+Stenman+UH%2C+Massobrio+M%2C+Van+Der+Zee+AG%2C+Vergote+I%2C+and+Katsaros+D%2C+Human+kallikrein+6+%28hK6%29%3A+%0A++a+new+potential+serum+biomarker+for+diagnosis+and+prognosis+of+ovarian+carcinoma.+J+Clin+Oncol%2C+2003.+21%286%29%3A+p.+1035-43%29%29.++Platform-based+assays+%28Roche%29+were+used+for+CA125%2C+%0A++CA15.3%2C+CA19.9%2C+and+CEA.++Unless+the+volume+was+insufficient+assays+were+run+in+duplicate+and+averaged.++Seven+markers+were+carried+over+to+phase+III+and+these+included+%0A++B7H4%2C+CA125%2C+CA15.3%2C+CA19.9%2C+CA72.4%2C+HE4%2C+and+HK+6.+++The+same+assays+were+used+except+that+a+platform-based+assay+was+available+for+CA72.4.+++The+two+0.3+aliquots+were+%0A++first+combined+and+homogenized.++UPCI+used+a+multi-plex+bead+assay+system+was+used+to+evaluate+34+markers+in+phase+II.++This+technique+is+described+in+%28Nolen+B%2C+Marrangoni+%0A++A%2C+Velikokhatnaya+L%2C+Prosser+D%2C+Winans+M%2C+Gorelik+E%2C+and+Lokshin+A%2C+A+serum+based+analysis+of+ovarian+epithelial+tumorigenesis.+Gynecol+Oncol%2C+2009.+112%281%29%3A+p.+47-54%29.++For+%0A++phase+III%2C+the+number+of+markers+was+reduced+to+8+but+the+same+technique+was+used.++For+the+phase+II+markers+included+in+the+Yale+panel%2C+these+markers+were+evaluated+using+a+%0A++multi-plex+bead+system+described+in+%28Visintin+I%2C+Feng+Z%2C+Longton+G%2C+Ward+DC%2C+Alvero+AB%2C+Lai+Y%2C+Tenthorey+J%2C+Leiser+A%2C+Flores-Saaib+R%2C+Yu+H%2C+Azori+M%2C+Rutherford+T%2C+Schwartz+PE%2C+%0A++and+Mor+G%2C+Diagnostic+markers+for+early+detection+of+ovarian+cancer.+Clin+Cancer+Res%2C+2008.+14%284%29%3A+p.+1065-72%29.++For+the+phase+III+specimens+the+same+markers+were+carried+over+%0A++but+the+analyses+were+performed+by+Laboratory+Corporation+of+America.%0A++</val>
</keyval>
<keyval type="vector">
<key>CAS.ProductReceivedTime</key>
<val>2010-04-25T20%3A51%3A34.743-07%3A00</val>
</keyval>
<keyval type="vector">
<key>SpecimenType</key>
<val>Serum</val>
<val>Serum</val>
</keyval>
</cas:metadata>
